Laboratorios Lesvi is Neuraxpharm’s manufacturing facility for Finished Dosage Forms (FDF) in Spain Barcelona and Dusseldorf – May 4, 2023 – Neuraxpharm Group (Neuraxpharm), the leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces that it has rebranded Laboratorios Lesvi to create Neuraxpharm Pharmaceuticals S.L. Read more…
Texas Medical Center (TMC) and the BioInnovation Institute (BII) announced today that three start-ups from BII will join a customized accelerator program tailored for helping startups build their US go-to-market strategy. The specialized accelerator is modeled and builds off the success of the TMC Innovation (TMCi) Health Tech Accelerator program. The Denmark Biobridge between the […]
Licensing deal gives iOnctura exclusive global development rights to novel TGFβ pathway inhibitor IOA-359 Pipeline expansion builds on iOnctura’s strategy of targeting multiple cancer survival pathways with a single drug; in this case targeting therapy resistance and immune evasion pathways in addition to IOA-359’s direct effects on the tumor Grant will accelerate iOnctura’s preclinical investigation of […]
Stockholm, May 3, 2023 – Vicore Pharma Holding AB (STO: VICO) (“Vicore”), unlocking the potential of a new class of drugs – angiotensin II type 2 receptor agonists (ATRAGs), today announces the first patient dosed with C21 in a clinical study of endothelial dysfunction. Endothelial dysfunction is a key driver of organ damage associated with […]
12 Abstracts and one Symposium further support potential of ensifentrine, a first-in-class, selective, dual inhibitor of PDE3 and PDE4 Conference call May 23 at 4:00 p.m. EDT / 9:00 p.m. BST LONDON and RALEIGH, N.C., May 02, 2023 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company […]
